498 results on '"Thamm, Douglas H."'
Search Results
152. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin
153. Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase I Evaluation
154. Transverse mode analysis of optofluidic intracavity spectroscopy of canine hemangiosarcoma
155. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target
156. Multiple Distinct Malignancies in Dogs: 53 Cases
157. Comparison of fluid types for resuscitation after acute blood loss in mallard ducks (Anas platyrhynchos)
158. Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses
159. Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma
160. Tuning the Magnetic Resonance Imaging Properties of Positive Contrast Agent Nanoparticles by Surface Modification with RAFT Polymers
161. Polymer-Modified Gadolinium Metal-Organic Framework Nanoparticles Used as Multifunctional Nanomedicines for the Targeted Imaging and Treatment of Cancer
162. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone
163. Systems biology approach to identification of biomarkers for metastatic progression in cancer
164. GS-9219—A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non–Hodgkin's Lymphoma
165. GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Has Antitumor Activity Against Naive and Melphalan-Refractory Spontaneous Myeloma in Pet Dogs.
166. GS-9219 - A Novel Prodrug of the Acyclic Nucleotide PMEG Demonstrates Significant Therapeutic Activity Against Spontaneous Non-Hodgkin’s Lymphoma as Modeled in Pet Dogs.
167. Successful Treatment of Acute Tumor Lysis Syndrome in a Dog with Multicentric Lymphoma
168. Serum concentrations of cardiac troponin I and cardiac troponin T in dogs with class IV congestive heart failure due to mitral valve disease
169. Aftershocks of Cancer Chemotherapy: Managing Adverse Effects
170. Combination Chemotherapy with L-Asparaginase, Lomustine, and Prednisone for Relapsed or Refractory Canine Lymphoma
171. Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma
172. The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines.
173. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line
174. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998–2004)
175. Does l-Asparaginase Influence Efficacy or Toxicity When Added to a Standard CHOP Protocol for Dogs with Lymphoma?
176. Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation
177. Cytotoxic Chemotherapy: New Players, New Tactics
178. SAHA and hemangiosarcoma: another view
179. IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma
180. Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery
181. Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985–1995)
182. Liposome‐Encapsulated Doxorubicin (Doxil) and Doxorubicin in the Treatment of Vaccine‐Associated Sarcoma in Cats
183. Evaluation of a 6‐Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with Lymphoma
184. What Is Your Diagnosis?
185. GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.
186. Prednisone and Vinblastine Chemotherapy for Canine Mast Cell Tumor—41 Cases (1992–1997)
187. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats
188. Contributors
189. Configuration of pathologic fractures in dogs with osteosarcoma following stereotactic body radiation therapy: A retrospective analysis.
190. Optofluidic Intracavity Spectroscopy of Canine Hemangiosarcoma.
191. Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses.
192. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
193. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.
194. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
195. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma
196. Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma.
197. Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
198. Alternating rabacfosadine and doxorubicin for treatment of naïve canine lymphoma.
199. VDX-111 targets proliferative pathways in canine cancer cell lines.
200. Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011‐2016) and comparison with doxorubicin‐based chemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.